查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1403513

到 2030 年甲沟炎治疗市场预测：按产品、类型、最终用户和地区分類的全球分析

Paronychia Treatment Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球甲沟炎治疗市场规模为 5.0734 亿美元，预计在预测期内复合年增长率为 9.2%，到 2030 年将达到 9.3942 亿美元。

甲沟炎是一种常见的指甲感染疾病，其特征是指甲和脚趾甲周围的皮肤发炎。它是由细菌、真菌或两者兼而有之引起的，会导致发红、肿胀和疼痛。治疗需要温水浴、适当的伤口引流、针对细菌感染的局部或口服抗生素以及针对真菌感染的口服抗真菌药物，并且在严重或復发的情况下可能需要手术治疗。

糖尿病患者增加

由于免疫系统减弱、神经损伤和血液循环减少，糖尿病患者更容易受到甲真菌病等指甲感染疾病，使他们更容易受到细菌和真菌指甲感染疾病。随着全球糖尿病盛行率的增加，糖尿病相关併发症（包括指甲疾病）的发生率也增加。糖尿病患者在控制感染疾病常常面临挑战，需要及时有效地治疗甲沟炎。

假药

假冒和不受监管的药物是一个严重的威胁，可能会给寻求甲沟炎治疗方法的人无效、不合格或有害的治疗方法。这些核准的药物缺乏品管以及适当的功效和安全标准，引起了医疗保健专业人员和患者对其治疗的可靠性和潜在副作用的担忧。我是。这些非正品产品的存在破坏了人们对市场提供的药品的信任并阻碍了市场的成长。

技术进步

创新技术可以改进配方、标靶化给药并增强诊断工具。奈米技术、经皮吸收贴片以及先进的影像检查和分子测试使治疗方法更加有效和精确。此外，远端医疗有助于远距咨询并扩大获得专业护理的机会。这些技术进步正在改善治疗效果、患者体验和甲沟炎治疗的整体前景，推动市场创新和成长机会。

认识有限

缺乏对甲沟炎、其症状以及及时接受医疗照护重要性的了解，可能会导致诊断和治疗的延迟。对预防措施和可用治疗方案认识不足可能会妨碍早期疗育并导致指甲感染疾病的进展。这种有限的认识会减少患者数量并阻碍有效甲沟炎治疗方法的采用，从而影响市场成长。

COVID-19 的影响

致命的冠状病毒迅速在世界各地传播，使医院不堪重负，占用了资源，并限制了获得非必要卫生服务的机会。这对医疗保健系统造成了重大干扰，不仅影响甲沟炎的诊断、治疗和管理，而且还延迟和减少了获得医疗保健服务的机会。遭受感染疾病和疼痛和发炎等不良影响的人们必须等待服务恢復才能解决他们的问题。

慢性甲沟炎部分预计将成为预测期内最大的部分

据估计，慢性甲沟炎所占比例最大。慢性甲沟炎是一种长期疾病，通常由真菌或细菌感染、刺激物或诱发因素（例如重复性创伤或潜在疾病）引起。慢性甲沟炎的治疗包括局部抗真菌药物和抗生素、口服疗法、温水浴以及解决潜在刺激的预防措施。慢性甲沟炎也会反覆復发，需要长期的专门治疗。因此，存在专门用于治疗此类疾病的市场。

庆大霉素软膏预计在预测期内复合年增长率最高

预计庆大霉素软膏细分市场在预测期内将出现良好的成长。庆大霉素软膏含有庆大霉素，这是一种对多种细菌有效的抗生素。当直接涂布在指甲的受影响区域时，庆大霉素软膏可以针对细菌感染，减少发炎并促进癒合。此外，其局部涂布和抗菌特性使其成为轻度至中度细菌性甲沟炎的有价值的治疗选择。该领域专门针对需要标靶抗菌治疗的患者，并为对抗甲沟炎等细菌性指甲感染疾病的局部治疗市场做出了贡献。

比最大的地区

由于医疗保健意识的提高、指甲感染疾病的上升以及医疗保健基础设施的改善，亚太地区在估计期间占据了最大的市场占有率。该地区多样化的人口和生活方式的变化导致甲沟炎发病率增加。此外，受甲沟炎影响的人数正在增加，治疗这一问题的支出也在增加，并且旨在改善卫生基础设施和提高对指甲感染疾病认识的有利政府措施的普及正在迅速增加。不断增长的市场正在推动市场需求生长。

复合年增长率最高的地区：

由于老年人口的迅速增加、人们对可行治疗方法的了解不断增加以及美国和加拿大等国家主要市场参与者的强大影响力，预计北美地区将在预测期内实现盈利增长。此外，尖端甲沟炎治疗方法（例如新的局部疗法、抗真菌药物和抗生素）的快速开拓可能会增加诊所和医院提供的治疗方法种类，并对市场产生积极影响。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球甲沟炎治疗市场：副产品

  • 莫匹罗星软膏
  • 庆大霉素软膏
  • 夫西地酸软膏
  • 双氯西林
  • 其他产品

第六章全球甲沟炎治疗市场：依类型

  • 慢性甲沟炎
  • 急性甲沟炎
  • 化脓性甲沟炎
  • 念珠菌性甲沟炎
  • 其他类型

第七章全球甲沟炎治疗市场：依最终用户分类

  • 皮肤科中心
  • 医院和诊所
  • 其他最终用户

第八章全球甲沟炎治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Glenmark Generics Ltd
  • Eli Lilly Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Jonakayem Pharma Formulation
  • Fougera Pharmaceuticals Inc
  • Allergen Plc
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • Perrigo New York Inc.
  • Novartis AG
  • Pfizer Inc.
  • Taro Pharmaceutical Industries
  • Sandoz International GmbH
Product Code: SMRC24738

According to Stratistics MRC, the Global Paronychia Treatment Market is accounted for $507.34 million in 2023 and is expected to reach $939.42 million by 2030 growing at a CAGR of 9.2% during the forecast period. Paronychia is a common nail infection characterized by inflammation of the skin surrounding the fingernail or toenail. This is caused by bacteria, fungi, or both, leading to redness, swelling, and pain. Treatment involves warm soaks, proper wound drainage, topical or oral antibiotics for bacterial infections, antifungal medications for fungal cases, and in severe or recurrent instances, surgical intervention may be necessary.

Market Dynamics:

Driver:

Significant rise in diabetes patients

Diabetic individuals are more susceptible to nail infections like paronychia due to compromised immune systems, nerve damage, and reduced blood circulation, making them susceptible to bacterial or fungal nail infections. With the escalating, global diabetes prevalence, there's been a corresponding increase in the incidence of diabetic-related complications, including nail disorders. Diabetic patients often experience challenges in managing infections, necessitating prompt and effective treatment for paronychia.

Restraint:

Counterfeit medications

Counterfeit or unregulated medications pose a serious threat, potentially offering ineffective, substandard, or even harmful treatments to individuals seeking remedies for paronychia. Such unauthorized drugs lack quality control, proper efficacy, and safety standards, raising concerns among healthcare professionals and patients about treatment reliability and potential adverse effects. The presence of these illegitimate products undermines trust in the market's offerings, hindering the market's growth.

Opportunity:

Advancements in technology

Innovative technologies offer improved drug formulations, targeted delivery systems, and enhanced diagnostic tools. Nanotechnology, transdermal patches, and sophisticated imaging or molecular testing enable more effective and precise treatment approaches. Additionally, telemedicine facilitates remote consultations, expanding access to specialized care. These technological advancements enhance treatment efficacy, patient experience, and the overall landscape of paronychia treatments, fostering opportunities for innovation and growth within the market.

Threat:

Limited awareness

Insufficient knowledge among individuals about paronychia, its symptoms, and the importance of seeking timely medical care may result in delayed diagnosis and treatment. Lack of awareness about preventive measures and available treatment options could hinder early intervention, leading to the progression of nail infections. This limited awareness impacts market growth by reducing the patient pool and impeding the adoption of effective paronychia treatments.

COVID-19 Impact

The deadly corona virus spread quickly around the world, overwhelming hospitals, redirecting resources, and restricting access to non-essential medical services. This caused major disruptions in healthcare systems that impacted paronychia diagnosis, treatment, and management, as well as delayed or decreased access to healthcare services. In order to get their problems resolved those who are experiencing infections and adverse consequences, including pain and inflammation, must wait for the services to resume.

The chronic paronychia segment is expected to be the largest during the forecast period

The chronic paronychia segment is estimated to hold the largest share. Chronic paronychia is a long-term condition that often arises from fungal or bacterial infections, irritants, or predisposing factors such as repetitive trauma or underlying health conditions. Treatments for chronic paronychia include topical antifungal or antibiotic medications, oral therapies, warm soaks, and preventive measures addressing potential irritants. Moreover, chronic paronychia requires long-term, specialised therapy due to its recurrent nature. As a result, there is a dedicated market focus on treating this type of illness.

The gentamicin ointment segment is expected to have the highest CAGR during the forecast period

The gentamicin ointment segment is anticipated to have lucrative growth during the forecast period. Gentamicin ointment contains gentamicin, an antibiotic effective against a wide range of bacteria. Applied directly to the affected nail area, gentamicin ointment targets bacterial infections, reducing inflammation and promoting healing. Furthermore, its localised application and antibacterial properties make it a valuable treatment option for mild-to-moderate bacterial paronychia cases. This segment caters specifically to individuals requiring targeted antimicrobial therapy, contributing to the market's array of topical treatments for addressing bacterial nail infections like paronychia.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to increasing healthcare awareness, a rising prevalence of nail infections, and improving healthcare infrastructure. The region's diverse population and changing lifestyles contribute to the growing incidence of paronychia. Moreover, due to the increased population base suffering from paronychia and their rising spending on the treatment of this issue, and the surging prevalence of favourable government initiatives aimed at improving healthcare infrastructure and promoting awareness about nail infections, this is driving the demand for market growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to a surge in the geriatric population, growing people's knowledge of viable treatments, and the robust presence of major market players in countries like the US and Canada. Moreover, the quick development of cutting-edge paronychia treatment alternatives, such as new topical therapies, antifungal medications, and antibiotics, which have increased the variety of treatment methods offered in clinics and hospitals, is likely to impact the market positively.

Key players in the market:

Some of the key players in the Paronychia Treatment Market include Glenmark Generics Ltd, Eli Lilly Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Jonakayem Pharma Formulation, Fougera Pharmaceuticals Inc, Allergen Plc, Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., Perrigo New York Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries and Sandoz International GmbH.

Key Developments:

In January 2023, The National Medical Products Administration of China announced that they have approved the mobocertinib for treatment of the adult patients with advanced and metastatic non-small lung cancer. The newly developed treatment technique was mostly experienced with mobocertinib including paronychia, diarrhoea, rash, and decreased appetite.

Products Covered:

  • Mupirocin Ointment
  • Gentamicin Ointment
  • Fusidic Acid Ointment
  • Dicloxacillin
  • Other Products

Types Covered:

  • Chronic Paronychia
  • Acute Paronychia
  • Pyogenic Paronychia
  • Candidal Paronychia
  • Other Types

End Users Covered:

  • Dermatology Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paronychia Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Mupirocin Ointment
  • 5.3 Gentamicin Ointment
  • 5.4 Fusidic Acid Ointment
  • 5.5 Dicloxacillin
  • 5.6 Other Products

6 Global Paronychia Treatment Market, By Type

  • 6.1 Introduction
  • 6.2 Chronic Paronychia
  • 6.3 Acute Paronychia
  • 6.4 Pyogenic Paronychia
  • 6.5 Candidal Paronychia
  • 6.6 Other Types

7 Global Paronychia Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Dermatology Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Paronychia Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Glenmark Generics Ltd
  • 10.2 Eli Lilly Company
  • 10.3 GlaxoSmithKline plc
  • 10.4 Teva Pharmaceutical Industries Ltd
  • 10.5 Jonakayem Pharma Formulation
  • 10.6 Fougera Pharmaceuticals Inc
  • 10.7 Allergen Plc
  • 10.8 Johnson & Johnson Services Inc.
  • 10.9 Bayer AG
  • 10.10 Merck & Co. Inc.
  • 10.11 Perrigo New York Inc.
  • 10.12 Novartis AG
  • 10.13 Pfizer Inc.
  • 10.14 Taro Pharmaceutical Industries
  • 10.15 Sandoz International GmbH

List of Tables

  • Table 1 Global Paronychia Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 4 Global Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 5 Global Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 6 Global Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 7 Global Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 10 Global Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 11 Global Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 12 Global Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 13 Global Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 14 Global Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 15 Global Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 16 Global Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 17 Global Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 18 North America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 20 North America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 21 North America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 22 North America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 23 North America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 24 North America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 25 North America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 27 North America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 28 North America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 29 North America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 30 North America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 North America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 33 North America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 34 North America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 35 Europe Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 37 Europe Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 38 Europe Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 39 Europe Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 40 Europe Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 41 Europe Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 42 Europe Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 43 Europe Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 44 Europe Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 45 Europe Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 46 Europe Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 47 Europe Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 48 Europe Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 Europe Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 50 Europe Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 51 Europe Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 52 Asia Pacific Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 54 Asia Pacific Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 55 Asia Pacific Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 56 Asia Pacific Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 57 Asia Pacific Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 58 Asia Pacific Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 59 Asia Pacific Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 61 Asia Pacific Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 62 Asia Pacific Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 63 Asia Pacific Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 64 Asia Pacific Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 65 Asia Pacific Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Asia Pacific Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 67 Asia Pacific Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 68 Asia Pacific Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 69 South America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 71 South America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 72 South America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 73 South America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 74 South America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 75 South America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 76 South America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 77 South America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 78 South America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 79 South America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 80 South America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 81 South America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 82 South America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 83 South America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 84 South America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 85 South America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 86 Middle East & Africa Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 88 Middle East & Africa Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 89 Middle East & Africa Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 90 Middle East & Africa Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 91 Middle East & Africa Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 92 Middle East & Africa Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 93 Middle East & Africa Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 94 Middle East & Africa Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 95 Middle East & Africa Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 96 Middle East & Africa Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 97 Middle East & Africa Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 98 Middle East & Africa Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 99 Middle East & Africa Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 100 Middle East & Africa Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 101 Middle East & Africa Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 102 Middle East & Africa Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)